Literature DB >> 16405869

Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.

Jarkko I Venäläinen1, J Arturo Garcia-Horsman, Markus M Forsberg, Aaro Jalkanen, Erik A A Wallén, Elina M Jarho, Johannes A M Christiaans, Jukka Gynther, Pekka T Männistö.   

Abstract

Prolyl oligopeptidase (POP) is a serine protease that specifically hydrolyses small peptides at the carboxyl end of the proline residue. POP has gained pharmaceutical interest, since its inhibitors have been shown to have antiamnesic properties in rat. We examined the effect of the 2(S)-substituents CN and COCH(2)OH at the P1 site of the parent inhibitors isophthalic acid 2(S)-(cyclopentanecarbonyl)pyrrolidine-l-prolyl-pyrrolidine amide and 4-phenylbutanoyl-l-prolyl-pyrrolidine and bulky 5-t-butyl group at the P2 site l-prolyl residue of the parent inhibitor 4-phenylbutanoyl-l-prolyl-pyrrolidine on the binding kinetics to the enzyme. In addition, we studied the duration of POP inhibition in the rat tissues in vivo after i.p. administration. CN and COCH(2)OH substituents at the P1 site pyrrolidine group were found to greatly increase the affinity of the inhibitor and the enzyme-inhibitor complex half-life. In addition, 5-t-butyl group at the P2 site l-prolyl residue increased the dissociation half-life of the enzyme-inhibitor complex, without much affecting the inhibitory potency. The duration of the inhibition in the rat tissues followed the inhibition kinetic properties in that the compounds with fast dissociation produced shorter inhibition in the rat tissues than the compounds with slow dissociation. The duration of POP inhibition of compounds was evidently not governed by their serum clearance. The fact that the in vivo pharmacodynamic behaviour of POP inhibitors can be predicted by their in vitro-properties may be of importance when designing therapeutically useful POP inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405869     DOI: 10.1016/j.bcp.2005.11.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

2.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

3.  Distribution of immunoreactive prolyl oligopeptidase in human and rat brain.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; Erkki Tupala; J Arturo Garcia-Horsman; Riitta Miettinen; Pekka T Männistö
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

4.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

6.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

7.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

8.  Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Authors:  Timo T Myöhänen; Elisa Pyykkö; Pekka T Männistö; Olli Carpen
Journal:  J Histochem Cytochem       Date:  2012-06-26       Impact factor: 2.479

9.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

10.  Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.

Authors:  Timo T Myöhänen; Jarkko I Venäläinen; J Arturo García-Horsman; Marjo Piltonen; Pekka T Männistö
Journal:  Histochem Cell Biol       Date:  2008-07-11       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.